tocilizumab,cevostamab
roche
['mmsm', 'tocilizumab', 'toci', 'cevostamab']
tocilizumab (8mg/kg) pre-cevostamab had lower crs (90% vs 38.7%, g3 3.2 vs 2.3%), with comparable orr however, higher rates of neutropenia (80% vs 40%) were seen with tcz, but was reversible very important data to start considering outpatient bite administrration #ash22 #mmsm 
| Hem/Onc fellow @WeillCornell | Interest in Plasma cell dyscrasias